Individuals between 20 and 39 years old experienced the steepest increase in distant-stage early-onset colorectal adenocarcinoma incidence between 2000 and 2016, with the youngest non-Hispanic Black and Hispanic populations ...
Jan 26, 2022
0
4
Independent drug action, not synergy nor additivity, accounted for the clinical efficacy of nearly all examined combination therapies involving immune checkpoint inhibitors in clinical trials, according to results from a ...
Jan 19, 2022
0
5
For patients with acute lymphoblastic leukemia (ALL) carrying the Philadelphia chromosome and whose disease relapsed after allogeneic hematopoietic stem cell transplantation (HCT), the two-year overall survival rate has nearly ...
Jan 12, 2022
0
8
The first classification of pediatric cancers soon to be published by the International Agency for Research on Cancer (IARC) as part of the new World Health Organization (WHO) Classification of Tumors series was summarized ...
Dec 17, 2021
0
6
Blood Cancer Discovery, a journal of the American Association for Cancer Research, has published a research article demonstrating a novel approach that may reduce a serious adverse effect associated with chimeric antigen ...
Dec 15, 2021
0
1
Among patients with hormone receptor-positive breast cancer treated with an aromatase inhibitor plus palbociclib (Ibrance), those who displayed a rising ESR1 mutation detected in their blood before disease progression doubled ...
Dec 9, 2021
0
3
Uterine cancers that developed in patients treated with tamoxifen (Soltamox) had fewer PI3K pathway mutations and may have instead been driven by tamoxifen-induced PI3K pathway activation, according to results presented at ...
Dec 9, 2021
0
2
Among patients with previously treated HER2-positive metastatic breast cancer, those who received pyrotinib plus capecitabine had longer overall survival than those who received lapatinib (Tykerb) plus capecitabine, according ...
Dec 8, 2021
0
2
The use of multigene sequencing as a therapeutic decision tool improved the outcomes for patients with metastatic breast cancer when the genomic alterations identified were ranked in the I/II tiers of the ESMO Scale for Clinical ...
Dec 8, 2021
0
0
Analysis of data from the I-SPY 2 clinical trial showed that race did not significantly affect several key measures of breast cancer treatment outcomes, including pathologic complete response and event-free survival, according ...
Dec 8, 2021
0
0
